Last reviewed · How we verify

Prolonged antibiotic treatment

Sheba Medical Center · FDA-approved active Small molecule

Prolonged antibiotic treatment is a Small molecule drug developed by Sheba Medical Center. It is currently FDA-approved for Chronic or recurrent bacterial infections, Biofilm-associated infections, Slow-growing bacterial pathogens. Also known as: Intravenous cefazolin 2 grams every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains.

Prolonged antibiotic treatment extends the duration of antimicrobial therapy to eliminate bacterial infections and reduce recurrence.

Prolonged antibiotic treatment extends the duration of antimicrobial therapy to eliminate bacterial infections and reduce recurrence. Used for Chronic or recurrent bacterial infections, Biofilm-associated infections, Slow-growing bacterial pathogens.

At a glance

Generic nameProlonged antibiotic treatment
Also known asIntravenous cefazolin 2 grams every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
SponsorSheba Medical Center
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Extended antibiotic courses maintain therapeutic drug concentrations in tissues and blood over longer periods, allowing complete eradication of bacterial pathogens and reducing the risk of relapse or chronic infection. This approach is particularly relevant for infections with slow-growing organisms, biofilm-associated infections, or conditions requiring sustained antimicrobial pressure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prolonged antibiotic treatment

What is Prolonged antibiotic treatment?

Prolonged antibiotic treatment is a Small molecule drug developed by Sheba Medical Center, indicated for Chronic or recurrent bacterial infections, Biofilm-associated infections, Slow-growing bacterial pathogens.

How does Prolonged antibiotic treatment work?

Prolonged antibiotic treatment extends the duration of antimicrobial therapy to eliminate bacterial infections and reduce recurrence.

What is Prolonged antibiotic treatment used for?

Prolonged antibiotic treatment is indicated for Chronic or recurrent bacterial infections, Biofilm-associated infections, Slow-growing bacterial pathogens.

Who makes Prolonged antibiotic treatment?

Prolonged antibiotic treatment is developed and marketed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).

Is Prolonged antibiotic treatment also known as anything else?

Prolonged antibiotic treatment is also known as Intravenous cefazolin 2 grams every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains.

What development phase is Prolonged antibiotic treatment in?

Prolonged antibiotic treatment is FDA-approved (marketed).

What are the side effects of Prolonged antibiotic treatment?

Common side effects of Prolonged antibiotic treatment include Antibiotic-associated diarrhea, Allergic reactions, Hepatotoxicity, Nephrotoxicity, Photosensitivity.

Related